A Novel BRCA1 Binding Domain on the Estrogen Receptor-Alpha Overcomes Tamoxifen Resistance
Abstract
Patients with BRCA1 mutations have an extraordinarily high risk of developing breast cancer in their lifetime. This proposal is designed to characterize a distinct BRCA1 binding site on the estrogen receptor-alpha that is responsible for suppressing tumor growth and estrogen activity in breast cancer stem cells. Highly specific molecules that mimic BRCA1 have strong potential to inhibit breast cancer stem cells, tumor growth, and improve overall survival. This new class of agents has the potential to fulfill a major unmet medical need by offering another therapy option for patients that become resistant to tamoxifen. In addition, this research could have major impact by providing a first in class therapeutic for patients that have a detected BRCA1 mutation and have chosen to watchfully wait instead of bilateral mastectomy.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210100
Entities
People
- Milton Brown
Organizations
- George Mason University
- United States Army